Transcutaneous electrical acupoint stimulation: Before the operation, the patient received transcutaneous electrical acupoint stimulation (TEAS) at bilateral Zusanli (ST 36), Neiguan (PC 6), and Ciliao (BL 32) acupoints with sterilized electrode patches. The stimulation intensity and current intensity that gave the patient an effective pricking sensation ("deqi") were maintained for 30 minutes. The stimulation method in the post-anesthesia care unit (PACU) was consistent with that before the operation.
Sham transcutaneous Electrical Acupoint Stimulation: Before the operation, disinfection patches with electrodes were applied to Zusanli (ST 36), Neiguan (PC 6), and Ciliao (BL 32) acupointst, but no electrical stimulation was conducted. The stimulation method in the post-anesthesia care unit (PACU) was the same as that before the operation.
Study summary
The purpose of this clinical trial is to understand the effect of percutaneous acupoint electrical stimulation on postoperative gastrointestinal dysfunction. It will also investigate the safety of percutaneous acupoint electrical stimulation. The main questions that this trial aims to answer are:
Can percutaneous acupoint electrical stimulation alleviate postoperative gastrointestinal dysfunction? Through which mechanisms do they function?
Participants will:
Preoperatively, patients were either given or not given percutaneous acupoint electrical stimulation.
Record their symptoms and biological indicators within 5 days after the operation.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age \> 18 years
* BMI \< 28 kg/m2
* ASA classification is I-III grade
* Laparoscopic urological procedures under general anesthesia, including but not limited to laparoscopic nephrectomy and laparoscopic radical prostatectomy for prostate cancer
* Normal comprehension ability, and the patient or his/her family members can cooperate in filling out the questionnaire
* Voluntary to sign the informed consent form
Exclusion Criteria:
* Comprehensive assessment of severe cardiovascular, pulmonary and cerebrovascular diseases (such as severe coronary heart disease, valve diseases, respiratory failure, cerebral hemorrhage, cerebral infarction, etc.)
* Preoperative use of analgesic and gastrointestinal motility drugs
* TEAS contraindications (having electronic devices in the body, skin damage or infection at the stimulation site)
* Previous history of TEAS or electro-acupuncture treatment
* Previous history of gastrointestinal surgery, long-term gastrointestinal motility disorders and severe intestinal diseases
* Pregnancy
Primary outcome measure(s)
I-FEED(Intake, Feeling nauseated, Emesis, physical Exam, and Duration of symptoms)Score — Three days after the operation The I-FEED score consists of five aspects: eating, nausea, vomiting, physical examination, and duration of symptoms. The lowest score is 0 and the highest is 14. The higher the score, the worse the result. The normal I-FEED score is 0-2 points. Postoperative gastrointestinal intolerance (POGI) is 3-5 points, and Postoperative gastrointestinal dysfunction (POGD) is ≥ 6 points.
Trial sites (1)
Facility
City
Region
Status
The First affiliated Hospital of Xiamen University
Xiamen
Fujian
Recruiting
More The First Affiliated Hospital of Xiamen University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.